Vaccines are biological preparations that improve immunity to a particular disease. They contain an agent that resembles a disease-causing microorganism and are administered to humans for preventing or treating infectious diseases. Rising prevalence of infectious diseases such as influenza, hepatitis, tetanus, diphtheria, and pneumonia has bolstered the demand for vaccines, thus driving the U.S. vaccine market. Furthermore, increasing focus of government on immunization programs has accelerated the adoption of vaccines.
The U.S. vaccine market is estimated to be valued at US$ 25 Billion in 2024 and is expected to exhibit a CAGR of 5.7% over the forecast period 2022-2024.
Key Takeaways
Key players operating in the U.S. Vaccine Market Size are copyright, Merck, Sanofi Pasteur, GlaxoSmithKline, and AstraZeneca Plc. The companies dominate the market with their extensive product portfolio and large distribution network across the nation.
Key opportunities in the market include development of novel therapeutic vaccines, growing awareness about preventable diseases, growing health expenditures. Production of combination vaccines targeting multiple diseases in one shot and expanding geographical reach by acquisitions are also potential opportunities.
Global expansion is a key focus area as the companies aim to leverage the U.S. as a strong base for research and development and then commercialize the vaccines across other high potential markets like EU, China, India, Brazil to tap into the huge growth opportunities.
Market Drivers
Increasing prevalence of infectious diseases and rising immunization rates are a major market driver. Growing awareness about vaccine-preventable diseases and various government initiatives to promote vaccination boosts adoption. Further, newer vaccine development for diseases like COVID-19 also supports growth.
Market Restrains
However, high costs associated with vaccine development as it requires extensive research and clinical trials is a major challenge. Also, stringent regulations and complex approval process hampers timely market introduction of new vaccines. Occasional vaccines shortages due to manufacturing issues create supply-demand gaps as well.
Segment Analysis
The U.S. Vaccine Market Regional Analysis is comprises of two dominant segments - pediatric vaccines and adult vaccines. Within pediatric vaccines, vaccines for diseases such as mumps, measles and rubella (MMR) dominate due to greater focus on early immunization and regular pediatric vaccination schedules. Most children in the U.S. receive MMR vaccination between 12-15 months as recommended by the Centers for Disease Control and Prevention. The MMR segment constitutes over 35% of the total pediatric vaccine market size owing to high volume administration and coverage of these diseases. Within adult vaccines, vaccines for influenza, pneumonia and herpes zoster top the segment. This is due to increased disease susceptibility and outbreaks in the adult population along with recommendations for universal immunization of adults above 65 years of age against pneumonia and herpes zoster.
Global Analysis
Regionally, the Western U.S. commands the largest market share currently. States such as California, Washington and Oregon have higher healthcare investments and healthcare infrastructure to drive routine immunization programs. However, vaccines markets in Southern U.S. states are experiencing faster growth. This can be attributed to improving access to healthcare through expanded public insurance programs and strengthening of existing networks for vaccination administration in these regions. Additionally, some Northeastern states like New York and New Jersey remain key revenue contributors with dense population and progressive healthcare policies supporting high vaccination rates. Overall, widespread immunization programs and better healthcare coverage across the country have enabled consistent market expansion over the past decade.
Get more insights on, U.S. Vaccine Market
For Deeper Insights, Find the Report in the Language that You want.
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments on “U.S. Vaccine Market is Anticipated to Witness High Growth Owing to Rising Immunization Rates”